Peddock Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Peddock Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-13	Closed	-$3K	–	265
2018 Q3	$3K	Hold	13	–	–	﹤0.01%	248
2018 Q2	$2K	Buy	+13	New	+$2.02K	﹤0.01%	254

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Peddock Capital Advisors's VRTX Position: Q4 2018 in Review

Peddock Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2018, closing a stake of 13 shares — an estimated $3K sold.

Peddock Capital Advisors first reported a position in VRTX in Q2 2018 and held it in 2 quarters. The position peaked at $3K in Q3 2018. 705 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.

Peddock Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Peddock Capital Advisors sold 13 Vertex Pharmaceuticals shares in Q4 2018, an estimated $3K.
Peddock Capital Advisors first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 2 quarters.
Peddock Capital Advisors's Vertex Pharmaceuticals position peaked at $3K in Q3 2018.
705 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.

Based on Peddock Capital Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.